Functional Patient-Reported Outcome Measures After Hip or Knee Arthroplasty: A Systematic Review and Content Analysis Using the International Classification of Functioning, Disability, and Health.

Autor: Karimijashni M; University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Abtahi F; Commonwealth University, Richmond, Virginia., Abbasalipour S; Western University, London, Ontario, Canada., Ranjbar P; University of New Brunswick, Fredericton, New Brunswick, Canada., Dabbagh A; University of Toronto, Toronto, Ontario, Canada., Westby M; Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada., Ramsay T; University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Beaulé PE; University of Ottawa and The Ottawa Hospital, Ottawa, Ontario, Canada., Poitras S; University of Ottawa, Ottawa, Ontario, Canada.

Publikováno v: Arthritis care & research [Arthritis Care Res (Hoboken)] 2024 Aug 09. Date of Electronic Publication: 2024 Aug 09.

Virtual wards for people with frailty: what works, for whom, how and why-a rapid realist review.

Autor: Westby M; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK., Ijaz S; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK., Savović J; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK., McLeod H; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK., Dawson S; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK., Welsh T; Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.; RICE - The Research Institute for the Care of Older People, Bath, UK.; Royal United Hospitals Bath NHS Foundation Trust, Bath, UK., Le Roux H; Churchdown Surgery, Parton Rd, Churchdown, Gloucester GL3 2JH, UK.; NHS England and NHS Improvement South West, Somerset, UK.; One Gloucestershire Integrated Care System Quality Improvement, Gloucester, UK., Walsh N; The National Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust, Bristol BS1 2NT, UK.; Centre for Health & Clinical Research, University of the West of England, Bristol BS16 1DD, UK., Bradley N; School of Nursing and Midwifery, Queens University Belfast, Belfast BT7 1NN, UK.

Publikováno v: Age and ageing [Age Ageing] 2024 Mar 01; Vol. 53 (3).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor

Autor: Jiang, X., Feyertag, F., Meehan, Conor J., McCormack, G.P., Travers, S.A., Craig, C., Westby, M., Lewis, M., Robertson, D.L.

Yes
Entry inhibitors represent a potent class of antiretroviral drugs that target a host cell protein, CCR5, an HIV-1 entry coreceptor, and not viral protein. Lack of sensitivity can occur due to preexisting virus that uses the CXCR4 coreceptor,

Externí odkaz: http://hdl.handle.net/10454/17292

sj-pdf-1-avc-10.1177_20402066211030380 - Supplemental material for V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Autor: Lewis, ME, Simpson, P, Mori, J, Jubb, B, Sullivan, J, McFadyen, L, van der Ryst, E, Craig, C, Robertson, DL, Westby, M

Supplemental material, sj-pdf-1-avc-10.1177_20402066211030380 for V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a35f2fdb01feee38c1e0dcdc841ab08